Steris PLC (STE) News
Filter STE News Items
STE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
STE News Highlights
- STE's 30 day story count now stands at 4.
- Over the past 28 days, the trend for STE's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about STE are COOK, ID and SHC.
Latest STE News From Around the Web
Below are the latest news stories about STERIS PLC that investors may wish to consider to help them evaluate STE as an investment opportunity.
Got $3,000? Here Are 2 Stocks That Will Make You RicherBioCryst Pharmaceuticals and Steris could both deliver outstanding returns for patient shareholders. |
Needham Keeps Their Hold Rating on Steris (STE)E ratio of 47.25. |
Needham Downgrades This Medical Equipment Stock Due To Lawsuit RiskA Cook County jury awarded $363 million to a woman who developed breast cancer after living close to a medical device sterilization facility run by Sterigenics, a unit of Sotera Health Co (NASDAQ: SHC). The lawsuit was related to ethylene oxide (EO) exposure, a disinfectant used to sterilize medical devices. The trial was the first of many to come against the Willowbrook plant operators, with more than 760 lawsuits against it in Cook County Circuit Court for toxic emissions. Needham expects conc |
Steris: Non-GAAP Valuations Supportive Of Substantial Upside |
Steris (STE) Down 0.8% Since Last Earnings Report: Can It Rebound?Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
STERIS' (NYSE:STE) Upcoming Dividend Will Be Larger Than Last Year'sThe board of STERIS plc ( NYSE:STE ) has announced that it will be increasing its dividend by 9.3% on the 23rd of... |
Here's Why Investors Should Retain STERIS (STE) Stock for NowInvestors are optimistic about STERIS' (STE) robust segmental performance and Cantel Medical buyout. |
STERIS (STE) Gains From Cantel Buyout, Supply Chain Issue StaysRevenue growth at STERIS' (STE) Applied Sterilization Technologies is driven by increased demand from medical device and biopharma customers. |
Needham Sticks to Its Buy Rating for Steris (STE)Needham analyst Michael Matson maintained a Buy rating on Steris (STE – Research Report) today and set a price target of $237.00. The company's shares closed last Wednesday at $203.81. According to TipRanks.com, Matson is a 4-star analyst with an average return of 3.8% and a 48.2% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Steris with a $248.00 average price target, implying a 14.0% upside from current levels. |
STERIS (STE) Q1 Earnings Match Estimates, EPS View DownSTERIS' (STE) revenues at AST improve driven by increased demand from medical device and biopharma customers. |